Outcome at ⩽42 days | Type of AAAAP | Number of trials (n) | Weighted event rates | RRR (95% CI) | NNT | |
---|---|---|---|---|---|---|
AAAAP | β lactam | |||||
*Abbreviations defined in glossary; weighted event rates, RRR, NNT, and CI calculated from data in article using a fixed effects model. | ||||||
†Event rates are not weighted. | ||||||
Rate of failure to achieve clinical cure or improvement | All | 18 (6749) | 17.8% | 18.4% | 3% (−7 to 13) | Not significant |
Macrolide or ketolide | 3 (566) | 18.1% | 19.9% | 19% (−14 to 42) | Not significant | |
Fluoroquinolone | 14 (5375) | 17.5% | 17.9% | 1% (−11 to 12) | Not significant | |
Quinolone or macrolide† | 1 (808) | 22% | 23% | 5% (−28 to 29) | Not significant |